MDxHealth SA

MDxHealth SA is a commercial-stage precision diagnostics company that provides urological solutions across the United States, the Netherlands, Belgium, Spain, Poland, Italy, and the rest of the European Union. It was founded in 2003, and changed its name from OncoMethylome Sciences SA to MDxHealth SA in October 2010. The company is headquartered in Herstal, Belgium.

MDxHealth SA offers novel prostate cancer genomic testing solutions, such as SelectMDx and ConfirmMDx. SelectMDx is a non-invasive urine test that helps physicians accurately diagnose prostate cancer while minimizing the use of invasive procedures. ConfirmMDx is an epigenetic test that provides further insight into the diagnosis of prostate cancer.

MDxHealth SA has developed a portfolio of products and services that are designed to meet the needs of urologists and their patients. Its products are designed to improve the accuracy and reliability of prostate cancer diagnosis and to reduce the use of unnecessary biopsies. The company also provides services such as laboratory testing, bioinformatics, and clinical data management.

MDxHealth SA is committed to providing the most advanced and accurate solutions to the urological community. It has established collaborations with a number of leading universities and hospitals, including the University of California, Los Angeles, the University of Southern California, and the University of Texas Southwestern Medical Center. The company has also been awarded numerous grants from the European Commission, the National Institutes of Health, and other organizations.